Chicago, IL 的 肝癌（肝細胞癌） 臨床試驗
16 項針對 肝癌（肝細胞癌） 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #26, Chicago
National Liver Cancer Screening Trial
招募中4 期
- Northwestern University, Chicago
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
招募中1/2 期
- Local Institution - 0107, Chicago
Defining the Ablative Dose for Y-90 TARE
招募中2 期
- Northwestern University, Chicago
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
招募中觀察性研究
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
招募中3 期
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Lurie Children's Hospital-Chicago, Chicago
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
招募中3 期
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
招募中2 期
- University of Chicago Comprehensive Cancer Center, Chicago
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
招募中觀察性研究
- Rush University Medical Center, Chicago
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
招募中1/2 期
- Northwestern University, Chicago
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
招募中1 期
- Clinical Trial Site, Chicago
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
招募中2 期
- Northwestern University, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
招募中4 期
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Chicago
The Dragon PLC Trial (DRAGON-PLC)
招募中
- Rush University Medical Center, Chicago
其他城市的 肝癌（肝細胞癌） 試驗
- Houston, TX31 項研究
- New York City, NY24 項研究
- Dallas, TX19 項研究
- Los Angeles, CA19 項研究
- Boston, MA18 項研究
- Cleveland, OH18 項研究
- Philadelphia, PA16 項研究
- Pittsburgh, PA15 項研究
- San Francisco, CA14 項研究
- Orange, CA14 項研究
- Jacksonville, FL14 項研究
- San Antonio, TX13 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌59 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肺癌41 項研究
- 肥胖症41 項研究
- 卵巢癌36 項研究
- 大腸直腸癌34 項研究
- 中風34 項研究
- 心臟衰竭31 項研究
- 過重29 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。